Search
Trihexyphenidyl
go.drugbank.com/drugs/DB00376ApprovedInvestigational[L31843] Trihexyphenidyl was granted FDA approval on 13 May 1949.[L31768]
International brands: Ea TenProducts: Nu-trihexyphenidylPrucalopride
go.drugbank.com/drugs/DB06480ApprovedInvestigational[A40254] Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,[A40250] in Canada on December 7, 2011 and by the FDA on December 17, 2018.[L4880]
Products: Nra-prucaloprideButabarbital
go.drugbank.com/drugs/DB00237ApprovedIllicitWithdrawn[A201977,A201980] Butabarbital was granted FDA approval on 5 June 1939.[L13613]
Inositol
go.drugbank.com/drugs/DB13178ApprovedInvestigationalWithdrawn[L1113] By the FDA, inositol is considered in the list of specific substances affirmed as generally recognized as safe (GRAS).[L2561]
Mixtures: Revitex Ampoules Et ComprimesCytochrome P450 4A11
go.drugbank.com/bio_entities/BE0000421TargetEnzymeHumansParticipates in omega-hydroxylation of (5Z,8Z,11Z,14Z)-eicosatetraenoic acid (arachidonate) to 20-hydroxyeicosatetraenoic acid (20-HETE), a signaling molecule acting both as vasoconstrictive and natriuretic
Synonyms: 20-HETE synthaseCortisone
go.drugbank.com/drugs/DB14681Investigational(From Martindale, The Extra Pharmacopoeia, 30th ed, p726)
Synonyms: Reichstein's substance Fa, Kendall's compound EGiredestrant
go.drugbank.com/drugs/DB19125InvestigationalGiredestrant is under investigation in clinical trial NCT06065748 (A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With Er-positive
Glutamic acid
go.drugbank.com/drugs/DB00142ApprovedInvestigationalNutraceuticalA peptide that is a homopolymer of glutamic acid.
Mixtures: Olimel 7.6% E, Olimel 4.4% ELuteinizing hormone
go.drugbank.com/drugs/DB14741ApprovedInvestigationalMixtures: MENOGON 75 IU LIYOFILIZE TOZ ICEREN AMPUL,5 ADET, MENOPUR 150 IU IM VE SC ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 5 ADETGedatolisib
go.drugbank.com/drugs/DB11896ApprovedInvestigationalCelcuity describes gedatolisib as the first FDA-approved therapy to inhibit the pathway comprehensively across all class I PI3K isoforms and both mTOR complexes. … [L63927] Gedatolisib was approved by the FDA on July 14, 2026, in combination with [fulvestrant], with or without [palbociclib], for adults with HR-positive, HER2-negative locally advanced or metastatic